Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rabinowitz

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Cell Reports|January 4, 2019
Flexible Nanopipettes for Minimally Invasive Intracellular Electrophysiology In VivoKrishna Jayant, Michael Wenzel, Yuki Bando, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2007
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligandsCraig R Woods, Michael D Hack, Brett D Allison, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2009
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacyMarna Pippel, Kristen Boyce, Hariharan Venkatesan, et al.
Journal of Biomolecular Screening|June 6, 2009
Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylasesKimon C Kanelakis, Heather L Palomino, Lina Li, et al.
Bioorganic & Medicinal Chemistry|February 22, 2008
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysisMark D Rosen, Michael D Hack, Brett D Allison, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 16, 2011
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailabilityMagda F Morton, Terrance D Barrett, Jamie Freedman, et al.
British Journal of Pharmacology|May 20, 2015
Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in ratsTerrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2009
Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinaseMark D Rosen, Craig R Woods, Steven D Goldberg, et al.
Journal of Medicinal Chemistry|November 16, 2001
Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)M H Rabinowitz, R C Andrews, J D Becherer, et al.
Antioxidants & Redox Signaling|February 24, 2015
Physiological Control of Nitric Oxide in Neuronal BACE1 Translation by Heme-Regulated eIF2α Kinase HRI Induces SynaptogenesisGerard Ill-Raga, Marta Tajes, Arnau Busquets-García, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Cell Reports|January 4, 2019
Flexible Nanopipettes for Minimally Invasive Intracellular Electrophysiology In VivoKrishna Jayant, Michael Wenzel, Yuki Bando, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2007
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligandsCraig R Woods, Michael D Hack, Brett D Allison, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2009
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacyMarna Pippel, Kristen Boyce, Hariharan Venkatesan, et al.
Journal of Biomolecular Screening|June 6, 2009
Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylasesKimon C Kanelakis, Heather L Palomino, Lina Li, et al.
Bioorganic & Medicinal Chemistry|February 22, 2008
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysisMark D Rosen, Michael D Hack, Brett D Allison, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 16, 2011
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailabilityMagda F Morton, Terrance D Barrett, Jamie Freedman, et al.
British Journal of Pharmacology|May 20, 2015
Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in ratsTerrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2009
Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinaseMark D Rosen, Craig R Woods, Steven D Goldberg, et al.
Journal of Medicinal Chemistry|November 16, 2001
Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)M H Rabinowitz, R C Andrews, J D Becherer, et al.
Antioxidants & Redox Signaling|February 24, 2015
Physiological Control of Nitric Oxide in Neuronal BACE1 Translation by Heme-Regulated eIF2α Kinase HRI Induces SynaptogenesisGerard Ill-Raga, Marta Tajes, Arnau Busquets-García, et al.
Pageof 5